Oramed Pharmaceuticals Inc Total Assets
Oramed Pharmaceuticals Inc total assets. Based on the latest financial reports, Oramed Pharmaceuticals Inc (ORMP) holds total assets worth $268.85 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ORMP market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Oramed Pharmaceuticals Inc (2005–2025)
Total assets of Oramed Pharmaceuticals Inc from 2005 to 2025. This chart illustrates how Oramed Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See ORMP stock price and chart for real-time trading data and today's change.
Oramed Pharmaceuticals Inc - Asset Composition Analysis
Oramed Pharmaceuticals Inc Total Assets Breakdown (December 2025)
Oramed Pharmaceuticals Inc total assets breakdown as of December 2025. Oramed Pharmaceuticals Inc's total assets of $268.85 Million consist of 57.7% current assets and 42.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.9% |
| Accounts Receivable | $4.64 Million | 2.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Oramed Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ORMP current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oramed Pharmaceuticals Inc's current assets represent 57.7% of total assets in 2025, a decrease from 100.0% in 2005.
- Cash Position: Cash and equivalents constituted 19.9% of total assets in 2025, up from -3209.1% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 2.0% of total assets.
Oramed Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Oramed Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Oramed Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.45 | 23.94 | 12.56 |
| Quick Ratio | 6.45 | 23.94 | 12.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $57.59 Million | $125.98 Million | $66.48 Million |
Oramed Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Oramed Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.65 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | 48.7% |
| Total Assets | $230.86 Million |
| Market Capitalization | $149.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oramed Pharmaceuticals Inc's assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Oramed Pharmaceuticals Inc's assets grew by 48.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Oramed Pharmaceuticals Inc (2005–2025)
The table below shows the annual total assets of Oramed Pharmaceuticals Inc from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $230.86 Million | +48.68% |
| 2024-12-31 | $155.28 Million | -29.60% |
| 2023-12-31 | $220.55 Million | +36.44% |
| 2022-12-31 | $161.64 Million | +26.28% |
| 2021-12-31 | $128.00 Million | +186.78% |
| 2020-12-31 | $44.63 Million | +28.76% |
| 2019-12-31 | $34.66 Million | -26.87% |
| 2018-12-31 | $47.40 Million | +22.43% |
| 2017-12-31 | $38.71 Million | -9.61% |
| 2016-12-31 | $42.83 Million | +62.52% |
| 2015-12-31 | $26.35 Million | +20.88% |
| 2014-12-31 | $21.80 Million | +151.75% |
| 2013-12-31 | $8.66 Million | +63.56% |
| 2012-12-31 | $5.29 Million | +22.40% |
| 2011-12-31 | $4.33 Million | +198.16% |
| 2010-12-31 | $1.45 Million | -55.52% |
| 2009-12-31 | $3.26 Million | -40.77% |
| 2008-12-31 | $5.51 Million | +184.31% |
| 2007-12-31 | $1.94 Million | +999.38% |
| 2006-12-31 | $176.19K | +13883.33% |
| 2005-12-31 | $1.26K | -- |
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for C… Read more